{"schema_version":"secwatch.filing_event.v1","accession":"0001680367-25-000044","form_type":"8-K","ticker":"STTK","cik":"0001680367","company_name":"Shattuck Labs, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.621883+00:00","generated_at":"2026-05-17T13:15:52.842836+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Shattuck Labs Q2 net loss narrows to $12.5M; IND submitted for SL-325 Phase 1, $103M private placement","bullets":["Net loss of $12.5M ($0.24/sh) vs $21.6M ($0.42/sh) YoY; R&D costs fell to $8.7M from $19.2M.","Cash $50.5M as of June 30; up to $103M from oversubscribed private placement led by OrbiMed to fund ops into 2029.","Submitted IND for SL-325 (DR3 blocking antibody) in July 2025; clearance expected Q3 2025; first dosing in Phase 1 expected Q3 2025.","Phase 1 trial in healthy volunteers to complete Q2 2026; funds expected to support operations into 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001680367-25-000044","json":"https://secwatch.observer/filing/0001680367-25-000044.json","markdown":"https://secwatch.observer/filing/0001680367-25-000044.md","text":"https://secwatch.observer/filing/0001680367-25-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680367/000168036725000044/0001680367-25-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680367/000168036725000044/sttk-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:15:52.842836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}